Cybin Inc. (HELP)

Market Cap	265.69M +78.9%
Revenue (ttm)	n/a
Net Income	-123.22M
EPS	-4.48
Shares Out	50.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	619,677
Open	5.36
Previous Close	5.34
Day's Range	5.16 - 5.44
52-Week Range	4.29 - 9.83
Beta	0.81
Analysts	Strong Buy
Price Target	51.50 (+869.87%)
Earnings Date	Jul 1, 2026

About HELP

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Eric So
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: HELP
• Website: https://cybin.com

Analyst Summary

According to 2 analysts, the average rating for HELP stock is "Strong Buy." The 12-month stock price target is $51.5, which is an increase of 869.87% from the latest price.

Price Target

$51.5

(869.87% upside)

Analyst Consensus: Strong Buy